NCT03454620View on ClinicalTrials.gov

A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

September 17, 2021

Study Completion Date

January 10, 2022

Conditions
Metastatic Colorectal CancerSolid Tumor
Interventions
DRUG

irinotecan

GC1118 combination with irinotecan

DRUG

FOLFIRI

GC1118 combination with FOLFIRI

Trial Locations (6)

Unknown

National Cancer Center, Gyeonggi-do

Seoul National University Bundang Hospital, Gyeonggi-do

Chonnam National University Hwasun Hospital, Jeonam

Seoul Asan Medical Center, Seoul

Seoul National Universtiy Hosipital, Seoul

Yonsei University Health Care System, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY